又一A股宣布：“摘帽”！

Core Viewpoint - ST Jiuzhitang announced the suspension of its stock trading for one day on May 6, 2025, with the resumption of trading on May 7, 2025, and the removal of other risk warnings, changing its stock name from "ST Jiuzhitang" to "Jiuzhitang" [4][6]. Company Announcement - The company has completed the rectification of internal control deficiencies, with non-operating fund occupation balance reduced to zero, and all income from non-company bank accounts transferred to the company's bank account [6]. - The company has strengthened risk compliance awareness and internal control management, implementing various rectification measures [6]. Financial Performance - In 2024, ST Jiuzhitang reported total revenue of 2.371 billion yuan, a year-on-year decrease of 19.91%, and a net profit attributable to shareholders of 216 million yuan, down 27.31% [8]. - For Q1 2025, the company achieved revenue of 806 million yuan, a decline of 25.36%, and a net profit of 117 million yuan, down 19.40% [10]. - The decline in performance is attributed to changes in medical insurance policies, market demand fluctuations, and rising raw material costs [10]. Market Context - The company operates in the traditional Chinese medicine sector, focusing on research, production, and sales, while also exploring innovative businesses such as stem cells and health services [8]. - The pharmaceutical market is experiencing intensified competition due to ongoing reforms in the medical and pharmaceutical management systems, impacting the company's traditional business model [10].